 CytoDyn Inc OTCQB:CYDY has announced encouraging early data from its long-hauler CD15 trial, which aimed to assess leronlimab administered as a weekly injection in people experiencing COVID-19 coronavirus symptoms for over 12 weeks. We are very pleased with the preliminary results from our long-haulers trial, which showed a greater improvement in the leronlimab patient group over placebo in 18 of 24 COVID-19 symptoms, said Chris Recknor, CytoDyns chief operating officer. 